h3 Search Results


recombinant mouse b7 h3  (R&D Systems)
93
R&D Systems recombinant mouse b7 h3
Recombinant Mouse B7 H3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse b7 h3/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant mouse b7 h3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
nbp2 59199 histone h3 chip novus biologicals  (Novus Biologicals)
94
Novus Biologicals nbp2 59199 histone h3 chip novus biologicals
Nbp2 59199 Histone H3 Chip Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nbp2 59199 histone h3 chip novus biologicals/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
nbp2 59199 histone h3 chip novus biologicals - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
recombinant human βig h3  (R&D Systems)
92
R&D Systems recombinant human βig h3
Recombinant Human βig H3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human βig h3/product/R&D Systems
Average 92 stars, based on 1 article reviews
recombinant human βig h3 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
histone 3  (Novus Biologicals)
94
Novus Biologicals histone 3
Histone 3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/histone 3/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
histone 3 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cd276  (R&D Systems)
94
R&D Systems cd276
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
Cd276, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd276/product/R&D Systems
Average 94 stars, based on 1 article reviews
cd276 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
b7 h3  (R&D Systems)
93
R&D Systems b7 h3
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
B7 H3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b7 h3/product/R&D Systems
Average 93 stars, based on 1 article reviews
b7 h3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
histone h3  (Novus Biologicals)
94
Novus Biologicals histone h3
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
Histone H3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/histone h3/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
histone h3 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
ina246  (Novus Biologicals)
90
Novus Biologicals ina246
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
Ina246, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ina246/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
ina246 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
goat anti b7 h3  (R&D Systems)
90
R&D Systems goat anti b7 h3
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
Goat Anti B7 H3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti b7 h3/product/R&D Systems
Average 90 stars, based on 1 article reviews
goat anti b7 h3 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
goat anti human 4igb7 h3 antibody  (R&D Systems)
99
R&D Systems goat anti human 4igb7 h3 antibody
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
Goat Anti Human 4igb7 H3 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti human 4igb7 h3 antibody/product/R&D Systems
Average 99 stars, based on 1 article reviews
goat anti human 4igb7 h3 antibody - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
rabbit anti citrullinated histone h3  (R&D Systems)
93
R&D Systems rabbit anti citrullinated histone h3
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
Rabbit Anti Citrullinated Histone H3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti citrullinated histone h3/product/R&D Systems
Average 93 stars, based on 1 article reviews
rabbit anti citrullinated histone h3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
human b7 h3 fc fusion protein  (R&D Systems)
94
R&D Systems human b7 h3 fc fusion protein
Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, <t>CD276,</t> and LRRC15) were highly expressed in most of the patient samples and cell lines.
Human B7 H3 Fc Fusion Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human b7 h3 fc fusion protein/product/R&D Systems
Average 94 stars, based on 1 article reviews
human b7 h3 fc fusion protein - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, CD276, and LRRC15) were highly expressed in most of the patient samples and cell lines.

Journal: Molecular Cancer Therapeutics

Article Title: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

doi: 10.1158/1535-7163.mct-21-0836

Figure Lengend Snippet: Figure 1. Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, CD276, and LRRC15) were highly expressed in most of the patient samples and cell lines.

Article Snippet: Antibodies for MT1-MMP (R&D Systems, FAB9181A, 1:40), MRC2 (kindly provided by Dr. Niels Behrendt, University of Copenhagen, Copenhagen, Denmark, clone 2h9, 1:500; ref. 27), and CD276 (R&D Systems, FAB1027P, 1:40) were added.

Techniques: Expressing, Mass Spectrometry

Figure 2. mRNA expression of MT1-MMP, MRC2, CD276,and LRRC15 in osteosarcoma, normal tissues, and other pediatric cancers. A–D, RNA-seq data showedMT1-MMP(A), MRC2 (B), CD276 (C), and LRRC15 (D) were overexpressed in osteosarcoma compared with a range of normal tissues. The boxes represent the Q1 and Q3 of the data. The bars represent the median. E–G, MT1-MMP (E), MRC2 (F), and CD276 (G) had higher expression in osteosarcoma compared with other pediatric cancers (OS, osteosarcoma; MEL, melanoma; RHB, rhabdomyosarcoma; CPC, choroid plexus carcinoma; HGG, high-grade glioma; EPD, ependymoma; ACT, adrenocortical carcinoma; WLM, Wilms’ tumor; NBL, neuroblastoma;LGG,low-grade glioma;RB, retinoblastoma;AML, acutemyeloid leukemia;MLL,mixed-lineage leukemia;MB, medulloblastoma; BALL, B-cell acute lymphoblastic leukemia; TALL, T-cell acute lymphoblastic leukemia). FPKM, fragments per kilobase million; TPM, transcripts per million.

Journal: Molecular Cancer Therapeutics

Article Title: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

doi: 10.1158/1535-7163.mct-21-0836

Figure Lengend Snippet: Figure 2. mRNA expression of MT1-MMP, MRC2, CD276,and LRRC15 in osteosarcoma, normal tissues, and other pediatric cancers. A–D, RNA-seq data showedMT1-MMP(A), MRC2 (B), CD276 (C), and LRRC15 (D) were overexpressed in osteosarcoma compared with a range of normal tissues. The boxes represent the Q1 and Q3 of the data. The bars represent the median. E–G, MT1-MMP (E), MRC2 (F), and CD276 (G) had higher expression in osteosarcoma compared with other pediatric cancers (OS, osteosarcoma; MEL, melanoma; RHB, rhabdomyosarcoma; CPC, choroid plexus carcinoma; HGG, high-grade glioma; EPD, ependymoma; ACT, adrenocortical carcinoma; WLM, Wilms’ tumor; NBL, neuroblastoma;LGG,low-grade glioma;RB, retinoblastoma;AML, acutemyeloid leukemia;MLL,mixed-lineage leukemia;MB, medulloblastoma; BALL, B-cell acute lymphoblastic leukemia; TALL, T-cell acute lymphoblastic leukemia). FPKM, fragments per kilobase million; TPM, transcripts per million.

Article Snippet: Antibodies for MT1-MMP (R&D Systems, FAB9181A, 1:40), MRC2 (kindly provided by Dr. Niels Behrendt, University of Copenhagen, Copenhagen, Denmark, clone 2h9, 1:500; ref. 27), and CD276 (R&D Systems, FAB1027P, 1:40) were added.

Techniques: Expressing, RNA Sequencing, Wilms Tumor Assay

Figure 3. MT1-MMP, MRC2, and CD276 are highly expressed cell-surface proteins in osteosarcoma. A and B, Western blots of MT1-MMP, MRC2, and CD276 in a panel of osteosarcoma cell lines (n ¼ 8; A) and PDXs (n ¼ 8; B). C, Flow cytometry analysis of 7 osteosarcoma cell lines. Gray plots represent unstained controls, and colored plots represent staining with MT1-MMP, MRC2, and CD276 antibodies.

Journal: Molecular Cancer Therapeutics

Article Title: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

doi: 10.1158/1535-7163.mct-21-0836

Figure Lengend Snippet: Figure 3. MT1-MMP, MRC2, and CD276 are highly expressed cell-surface proteins in osteosarcoma. A and B, Western blots of MT1-MMP, MRC2, and CD276 in a panel of osteosarcoma cell lines (n ¼ 8; A) and PDXs (n ¼ 8; B). C, Flow cytometry analysis of 7 osteosarcoma cell lines. Gray plots represent unstained controls, and colored plots represent staining with MT1-MMP, MRC2, and CD276 antibodies.

Article Snippet: Antibodies for MT1-MMP (R&D Systems, FAB9181A, 1:40), MRC2 (kindly provided by Dr. Niels Behrendt, University of Copenhagen, Copenhagen, Denmark, clone 2h9, 1:500; ref. 27), and CD276 (R&D Systems, FAB1027P, 1:40) were added.

Techniques: Western Blot, Flow Cytometry, Staining

Figure 4. IHC staining showed high membranous positivity of MT1-MMP, MRC2, and CD276 in most osteosarcoma patient samples and PDXs. A–C, Representative membrane- staining examples of MT1-MMP in a patient sample (A), PDX (B), and testes (negative control; C). D–F, Representative membrane-staining examples of MRC2 in a patient sample (D), PDX (E), and placenta (negative control; F). G–I, Representative membrane-staining examples of CD276 in a patient sample (G), PDX (H), and placenta (mild positive; I). J and K, Summary of IHC staining H-score of MT1-MMP, MRC2, and CD276 in the tissue microarray for 37 patientswith osteosarcoma (J) and 19 PDX models (K). Boxes indicate SD, and error bars represent data range.

Journal: Molecular Cancer Therapeutics

Article Title: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

doi: 10.1158/1535-7163.mct-21-0836

Figure Lengend Snippet: Figure 4. IHC staining showed high membranous positivity of MT1-MMP, MRC2, and CD276 in most osteosarcoma patient samples and PDXs. A–C, Representative membrane- staining examples of MT1-MMP in a patient sample (A), PDX (B), and testes (negative control; C). D–F, Representative membrane-staining examples of MRC2 in a patient sample (D), PDX (E), and placenta (negative control; F). G–I, Representative membrane-staining examples of CD276 in a patient sample (G), PDX (H), and placenta (mild positive; I). J and K, Summary of IHC staining H-score of MT1-MMP, MRC2, and CD276 in the tissue microarray for 37 patientswith osteosarcoma (J) and 19 PDX models (K). Boxes indicate SD, and error bars represent data range.

Article Snippet: Antibodies for MT1-MMP (R&D Systems, FAB9181A, 1:40), MRC2 (kindly provided by Dr. Niels Behrendt, University of Copenhagen, Copenhagen, Denmark, clone 2h9, 1:500; ref. 27), and CD276 (R&D Systems, FAB1027P, 1:40) were added.

Techniques: Immunohistochemistry, Membrane, Staining, Negative Control, Microarray